Friedhelm Blobel - SciClone Pharmaceuticals Insider

CEO and President Executive Director and Member of Bus. Devel. Committee

Dr. Friedhelm Blobel, Ph.D. is President, Chief Executive Officer, Director of SciClone Pharmaceuticals, Inc. He has served as our President, Chief Executive Officer and as a Director since June 2006. From July 2000 to 2006, Dr. Blobel was President, CEO and a Director of Gryphon Therapeutics, Inc., a South San Francisco based biopharmaceutical company. Prior to joining Gryphon Therapeutics in July 2000, Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group including responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer and General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals, Senior Vice President of Research and Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana
Age: 65  CEO Since 2013  Ph.D    
650-358-3456  www.sciclone.com
Friedhelm Blobel EducationBlobel earned his doctorate degree with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany.

Friedhelm Blobel Latest Insider Trades

Management Efficiency

The company has return on total asset (ROA) of 0.15 % which means that it generated profit of $0.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 7.9 % meaning that it created $7.9 on every $100 dollars invested by stockholders.
The company currently holds 1.65 M in liabilities with Debt to Equity (D/E) ratio of 0.01 which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals Inc has Current Ratio of 7.33 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the People?s Republic of China, the United States, and Hong Kong. SciClone Pharmaceuticals Inc (SCLN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 590 people. SciClone Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification and specializes in Healthcare with concentration in Pharmaceuticals And Biosciences.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add SciClone Pharmaceuticals Inc to your portfolio

Top Management

SciClone Pharmaceuticals Leadership Team
Charles Meng, VP
Richard Hawkins, Director
Gregg Lapointe, Director, MBA
Hong Zhao, CEO
Wilson Cheung, CFO
Nancy Chang, Director, Ph.D
Anthony Lapointe, Director, MBA
Lan Xie, CFO, MBA
Raymond Low, President, MBA
Robert King, President, Ph.D
Simon Li, Director, MBA
Min Yin, VP
Jon Saxe, Chairman
Friedhelm Blobel, CEO, Ph.D

Stock Performance

SciClone Pharmaceuticals Performance Indicators